Mazen Noureddin

MD, MHSc

Dr. Noureddin began his hepatology research during his internal medicine residency at the University of Southern California (USC). Following his residency, he moved to the National Institutes of Health (NIH), where he was enrolled in a three-year Hepatology Fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, which included a combined NIH/Duke University Master of Health Sciences in Clinical Research certification.

Subsequent to NIH fellowship, Dr. Noureddin completed his Gastroenterology fellowship at the University of California, San Diego, where he focused on NAFLD and NASH and assessing the clinical utility of a new liver-imaging technique, MRI-proton density fat fraction (MRI-PDFF). This scanning methodology is currently considered the new reference standard for the imaging of fatty liver in NAFLD patients.

Dr. Noureddin returned to the University of Southern California (USC) and established a fatty liver program at USC to continue research on NAFLD/NASH, while conducting translational research and clinical trials. He joined Cedars-Sinai in 2015 to establish the Cedars-Sinai Fatty Liver Program. Dr. Noureddin has conducted more than 35 investigational, translational, and clinical studies of novel treatments for nonalcoholic steatohepatitis (NASH).

He has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the Chair of the AASLD NASH Special Interest Education Sub-committee and serves on the editorial board for the journals “Clinical Gastroenterology and Hepatology (CGH)” and “Gastroenterology.” He is funded by the National Cancer Institute.

​